Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis

被引：1
|
作者：
Chang, Hui-Chin [1 ,2 ,3 ]
Gau, Shuo-Yan [3 ,4 ]
机构：
[1] Chung Shan Med Univ Hosp, Taichung, Taiwan
[2] Chung Shan Med Univ Hosp, Evidence Based Med Ctr, Taichung, Taiwan
[3] Chung Shan Med Univ, Sch Med, 110 Sec 1, Jianguo N Rd, Taichung 40201, Taiwan
[4] Chi Mei Med Ctr, Inst Med Educ, Tainan, Taiwan
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2023年 / 58卷 / 11-12期
关键词：
D O I：
10.1111/apt.17697
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LINKED CONTENT This article is linked to Kochhar et al papers. To view these articles, visit and
引用
收藏
页码：1242 / 1242
页数：1
相关论文
共 50 条
  • [31] SAFETY OF ANTI-TUMOR NECROSIS FACTOR AGENTS COMPARED TO USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS
    Chaaban, Lara
    Huang, Jane
    Melia, Joanna
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S82 - S83
  • [32] Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study
    Meyer, Antoine
    Fumery, Mathurin
    Peyrin-Biroulet, Laurent
    Filippi, Jerome
    Altwegg, Romain
    Bouhnik, Yoram
    Serrero, Melanie
    Laharie, David
    Roblin, Xavier
    Nachury, Maria
    Abitbol, Vered
    Cadiot, Guillaume
    Nancey, Stephane
    Allez, Matthieu
    Gilletta, Cyrielle
    Vuitton, Lucine
    Savoye, Guillaume
    Nahon, Stephane
    Bourrier, Anne
    Buisson, Anthony
    Bouguen, Guillaume
    Bourreille, Arnaud
    Viennot, Stephanie
    Carbonnel, Franck
    Amiot, Aurelien
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (12) : 1454 - 1462
  • [33] Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
    Loftus, Edward V., Jr.
    Baumgart, Daniel C.
    Gecse, Krisztina
    Kinnucan, Jami A.
    Connelly, Susan B.
    Salese, Leonardo
    Su, Chinyu
    Kwok, Kenneth K.
    Woolcott, John C.
    Armuzzi, Alessandro
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (05) : 744 - 751
  • [34] Vedolizumab for the treatment of ulcerative colitis
    Stallmach, Andreas
    Schmidt, Carsten
    Teich, Niels
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (02) : 165 - 175
  • [35] Vedolizumab for the treatment of ulcerative colitis
    Rietdijk, Svend T.
    D'Haens, Geert R.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (04) : 423 - 430
  • [36] Subcutaneous vedolizumab for ulcerative colitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (11): : 826 - 826
  • [37] Vedolizumab is superior than Adalimumab in Patients with Ulcerative colitis
    Di Lellis, Maddalena Angela
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (01):
  • [38] Subcutaneous vedolizumab for ulcerative colitis
    Brierley, Rob
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (01): : 16 - 16
  • [39] Vedolizumab for the treatment of ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (01) : 129 - 135
  • [40] Efficacy and safety of retreatment with vedolizumab in patients with ulcerative colitis
    Sands, B. E.
    Shafran, I.
    Farraye, F. A.
    Cheifetz, A. S.
    Abhyankar, B.
    Sankoh, S.
    Smyth, M.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S37 - S37
12345